Last reviewed · How we verify
NCT03703154
Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Immediate Release Tacrolimus to Slow Release Envarsus
trial testing Envarsus in End Stage Renal Disease in 30 participants. Completed in 3 March 2021.
3 March 2021
Quick facts
| Lead sponsor | University of Kansas Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 25 October 2018 |
| Primary completion | 3 March 2021 |
| Estimated completion | 3 March 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Envarsus — full drug profile →
- Tacrolimus (TACROLIMUS) — full drug profile →
Conditions studied
- End Stage Renal Disease — all drugs for End Stage Renal Disease →
Sponsor
University of Kansas Medical Center
Who can join
Adults 18 to 85, any sex, with End Stage Renal Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to learn if conversion from immediate release tacrolimus to Envarsus improves cerebral blood flow, brain blood flow response to exercise, and cognition.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03703154
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Envarsus
Trials testing the same drug.
- NCT05655273 — Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients · Phase 4 · enrolling by invitation
- NCT04973982 — ENvarsus for Impaired Glucose Tolerance Post REnal transplAnT · NA · withdrawn
- NCT03823768 — Envarsus Neurotoxicity Burden in Liver Transplant Patients · Phase 4 · completed
- NCT03603548 — Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patient · NA · unknown
- NCT03461445 — Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients · Phase 4 · completed
Other recruiting trials for End Stage Renal Disease
Currently open trials in the same condition.
- NCT06257134 — Impact on Quality of Life of Symptoms Routine E-monitoring Among Dialysis Patients. · NA · recruiting
- NCT06310161 — Light Therapy in End Stage Kidney Disease · NA · recruiting
- NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
- NCT06422871 — PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis · recruiting
- NCT06861816 — Ventilatory Functions and Physical Intolerance in ESRD Adolescents: Response to Program of Walking With Dogs · NA · recruiting
Other University of Kansas Medical Center trials
Trials by the same sponsor.
- NCT06636214 — Adapting Changing Talk: Online (CHATO) to CHATO-Inclusive · NA · not yet recruiting
- NCT07528963 — KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice · NA · enrolling by invitation
- NCT07463755 — Low-Fidelity Driving Simulator Training in Parkinson's Disease. · NA · not yet recruiting
- NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
- NCT07491510 — Improving Prenatal Care to Reduce Early Onset Preeclampsia in Low-Income · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03703154 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Kansas Medical Center
- Last refreshed: 27 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03703154.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing